NOV 23, 2015 07:00 AM PST

WEBINAR: New specificities in the antiphospholipid syndrome: The importance of testing for aPS/PT and anti-β2 Domain 1 antibodies (Spanish Language)

Speakers
  • Managing Editor of the journal Lupus, Chairman of the Antiphospholipid Syndrome Laboratory Diagnostics and Trends Task Force, Executive Committee Member of the APS alliance for clinical tri
    Biography
      Dr Maria Laura Bertolaccini was born in Rosario, Argentina where she graduated from the Medical School at the National University of Rosario. Shejoined the Lupus Unit in 1996 as a Clinical Research Fellow. In 2004, she was awarded her PhD degree by King's College London. Dr Bertolaccini is the Managing Editor of Lupus an international journal. She is the Co-Chair of the Standardisation subcommittee on Lupus anticoagulant and antiphospholipid antibodies at the International Society for Thrombosis and Haemostasis (ISTH), Chairman of the Antiphospholipid Syndrome Laboratory Diagnostics and Trends Task Force andE xecutive Committee Member of the Antiphospholipid syndrome alliance for clinical trials and international networking (APS Action). Dr Bertolaccini has published 84 peer-review papers, 2 books, 11 book chapters and presented more than 85 abstracts at national/international meetings.

    Abstract:
    Presence of anti-PS/PT IgG or IgM antibodies indicates a high risk category of patients

    Antiphospholipid antibodies are not directed against phospholipids, but rather to phospholipid-protein complexes.  Recent evidence suggests that antibodies to the complex of PS and PT (PS/PT) identifies a distinct subset of patients with very high likelihood of adverse events. Antibodies targeted to either PS or PT yield less clinically relevant information as antibodies towards the PS/PT complex.

    Recent studies have shown that the risk of thrombotic events increases with the number of positive test results in APS patients and aPL carriers. Triple positivity for LAC, anti-β2GP1, and PS/PT demonstrated the highest diagnostic accuracy out of 23 possible combinations of aPL tests.

    Inclusion of PS/PT testing into routine testing can improve patient outcome.

    Anti-β2GP1 domain 1 antibodies are highly specific for the diagnosis of APS and may help support therapeutic decision making

    Anti-β2GP1 antibodies target multiple epitopes in the same molecule. A growing body of evidence indicates that domain 1 is the most relevant epitope targeted by anti-β2GP1 antibodies in patients with APS. Many studies have shown that anti-domain 1 antibodies identify a distinct population of patients with a high risk of thromboembolic events, despite therapy.  In addition, carriers are high risk to develop a first thromboembolic event.
     

    Show Resources
    You May Also Like
    OCT 02, 2019 11:00 AM PDT
    OCT 02, 2019 11:00 AM PDT
    DATE: October 2, 2019TIME: 11:00am PDT, 2:00pm EDT Ditch the Excel spreadsheets and manage your molecular workflows entirely in your LIMS Achieve configuration of molecular workf...
    AUG 27, 2019 09:00 AM PDT
    C.E. CREDITS
    AUG 27, 2019 09:00 AM PDT
    DATE: August 27, 2019 TIME: 9:00am PDT, 12:00pm EDT Immunotherapies targeting PD-1 or PD-L1 have proven remarkably effective for treating cancer in some patients, with considerabl...
    JUN 05, 2019 05:00 PM CEST
    C.E. CREDITS
    JUN 05, 2019 05:00 PM CEST
    DATE: June 5, 2019TIME: 8:00am PDT, 11:00am EDT, 5:00pm CEST Eukaryotic cell cultures respond to the most subtle influence. Apart from the risk of contamination, minimal chan...
    JUL 30, 2019 10:00 AM PDT
    C.E. CREDITS
    JUL 30, 2019 10:00 AM PDT
    DATE: July 30, 2019TIME: 10:00am PT/ 1:00pm ET The importance of building a validation structure within your lab cannot be overstated. Once in place, the ability to identify high...
    SEP 05, 2019 04:00 PM CEST
    C.E. CREDITS
    SEP 05, 2019 04:00 PM CEST
    DATE: September 5, 2019TIME: 7:00am PT, 10:00am ET, 4:00pm CEST PCR (Polymerase Chain Reaction) has gone through a massive evolution since its development in 1983. Besides it...
    JUN 19, 2019 10:00 AM PDT
    JUN 19, 2019 10:00 AM PDT
    DATE: June 19, 2019TIME: 10:00am PDT, 1:00pm EDT As we develop new methods to create more biologically relevant models for research in understanding disease etiology and in...
    Loading Comments...
    Show Resources